Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model

Journal of Immunology

Volumn 190, Issue 1, 2013, Pages 447-457

  Fanning, Stacey L ^a   Zilberberg, Jenny ^a   Stein, Johann ^a   Vazzana, Kristin ^a   Berger, Stephanie A ^a   Korngold, Robert ^a   Friedman, Thea M ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR V BETA CHAIN; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; COMPLEMENTARITY DETERMINING REGION; COMPLEMENTARITY DETERMINING REGION 3; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOPATHOLOGY; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MORTALITY; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; SENSITIZATION; TUMOR IMMUNITY;

ANIMALS; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMPLEMENTARITY DETERMINING REGIONS; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA;

EID: 84871839866     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201641     Document Type: Article

References (55)

1. Korngold, R., and J. Sprent. 1978. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice: prevention by removing mature T cells from marrow. J. Exp. Med. 148: 1687-1698. (Pubitemid 9084041)
2. Korngold, R., and J. Sprent. 1981. H-2 restriction of T cells causing lethal graft-versus-host disease across minor histocompatibility barriers in mice. Transplant. Proc. 13: 1217-1219. (Pubitemid 11159149)
3. + T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J. Exp. Med. 165: 1552-1564.
4. Hamilton, B. L., M. J. Bevan, and R. Parkman. 1981. Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens. J. Immunol. 126: 621-625. (Pubitemid 11136723)
5. Fowler, D. H. 2006. Shared biology of GVHD and GVT effects: potential methods of separation. Crit. Rev. Oncol. Hematol. 57: 225-244. (Pubitemid 43238327)
6. Horowitz, M. M., R. P. Gale, P. M. Sondel, J. M. Goldman, J. Kersey, H. J. Kolb, A. A. Rimm, O. Ringdén, C. Rozman, B. Speck, et al. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-562. (Pubitemid 20069191)
7. Marmont, A. M., M. M. Horowitz, R. P. Gale, K. Sobocinski, R. C. Ash, D. W. van Bekkum, R. E. Champlin, K. A. Dicke, J. M. Goldman, R. A. Good, et al. 1991. T-cell depletion of HLA-identical transplants in leukemia. Blood 78: 2120-2130.
8. Pavletic, S. Z., S. Kumar, M. Mohty, M. de Lima, J. M. Foran, M. Pasquini, M. J. Zhang, S. Giralt, M. R. Bishop, and D. Weisdorf. 2010. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol. Blood Marrow Transplant. 16: 871-890.
9. Miller, J. S., E. H. Warren, M. R. van den Brink, J. Ritz, W. D. Shlomchik, W. J. Murphy, A. J. Barrett, H. J. Kolb, S. Giralt, M. R. Bishop, et al. 2010. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol. Blood Marrow Transplant. 16: 565-586.
10. + T cell responses to minor histocompatibility antigens involved in graft-versus-host disease. J. Immunol. 161: 41-48.
11. Jones, S. C., T. M. Friedman, G. F. Murphy, and R. Korngold. 2004. Specific donor Vβ-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens. Biol. Blood Marrow Transplant. 10: 91-105. (Pubitemid 38145863)
12. + T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial tissue infiltrate. Biol. Blood Marrow Transplant. 7: 2-13.
13. + T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 7: 187-196.
14. Korngold, R., C. Leighton, and T. Manser. 1994. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 58: 278-287. (Pubitemid 24252277)
15. Zilberberg, J., D. McElhaugh, L. N. Gichuru, R. Korngold, and T. M. Friedman. 2008. Inter-strain tissue-infiltrating T cell responses to minor histocompatibility antigens involved in graft-versus-host disease as determined by Vβ spectratype analysis. J. Immunol. 180: 5352-5359.
16. Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22: 745-763. (Pubitemid 38680440)
17. 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood 103: 1542-1547.
18. Passweg, J. R., P. Tiberghien, J. Y. Cahn, M. R. Vowels, B. M. Camitta, R. P. Gale, R. H. Herzig, D. Hoelzer, M. M. Horowitz, N. Ifrah, et al. 1998. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 21: 153-158. (Pubitemid 28044008)
19. Kolb, H. J., A. Schattenberg, J. M. Goldman, B. Hertenstein, N. Jacobsen, W. Arcese, P. Ljungman, A. Ferrant, L. Verdonck, D. Niederwieser, et al. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86: 2041-2050.
20. Apperley, J. F., L. Jones, G. Hale, H. Waldmann, J. Hows, Y. Rombos, C. Tsatalas, R. E. Marcus, A.W. Goolden, E. C. Gordon-Smith, et al. 1986. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1: 53-66. (Pubitemid 17070365)
21. Small, T. N., E. B. Papadopoulos, F. Boulad, P. Black, H. Castro-Malaspina, B. H. Childs, N. Collins, A. Gillio, D. George, A. Jakubowski, et al. 1999. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 93: 467-480. (Pubitemid 29035728)
22. Kurokawa, T., K. Fischer, H. Bertz, S. Hoegerle, J. Finke, and A. Mackensen. 2002. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation. Int. J. Cancer 101: 52-60. (Pubitemid 34832997)
23. Friedman, T. M., K. Goldgirsh, S. A. Berger, J. Zilberberg, J. Filicko-O'Hara, N. Flomenberg, M. Donato, S. D. Rowley, and R. Korngold. 2008. Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vβ use: a new paradigm for designer allogeneic blood and marrow transplantation. Blood 112: 3517-3525.
24. Higgins, J. P., M. B. Bernstein, and J. W. Hodge. 2009. Enhancing immune responses to tumor-associated antigens. Cancer Biol. Ther. 8: 1440-1449.
25. Leen, A. M., C. M. Rooney, and A. E. Foster. 2007. Improving T cell therapy for cancer. Annu. Rev. Immunol. 25: 243-265. (Pubitemid 46697909)
26. el-Shami, K., B. Tirosh, E. Bar-Haim, L. Carmon, E. Vadai, M. Fridkin, M. Feldman, and L. Eisenbach. 1999. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur. J. Immunol. 29: 3295-3301.
27. Sallusto, F., D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
28. Unsoeld, H., and H. Pircher. 2005. Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7. J. Virol. 79: 4510-4513. (Pubitemid 40388388)
29. Chen, B. J., X. Cui, G. D. Sempowski, C. Liu, and N. J. Chao. 2004. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood 103: 1534-1541. (Pubitemid 38168675)
30. + T cells do not induce graft-versus-host disease. J. Clin. Invest. 112: 101-108.
31. Chen, B. J., D. Deoliveira, X. Cui, N. T. Le, J. Son, J. F. Whitesides, and N. J. Chao. 2007. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 109: 3115-3123. (Pubitemid 46482115)
32. + memory stem cells in graft-versus-host disease. Nat. Med. 11: 1299-1305.
33. Zhang, Y., G. Joe, E. Hexner, J. Zhu, and S. G. Emerson. 2005. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J. Immunol. 174: 3051-3058. (Pubitemid 40279726)
34. + T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood 103: 3970-3978.
35. Juchem, K. W., B. E. Anderson, C. Zhang, J. M. McNiff, A. J. Demetris, D. L. Farber, A. J. Caton, W. D. Shlomchik, and M. J. Shlomchik. 2011. A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood 118: 6209-6219.
36. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102: 9571-9576.
37. Dutt, S., D. Tseng, J. Ermann, T. I. George, Y. P. Liu, C. R. Davis, C. G. Fathman, and S. Strober. 2007. Naive and memory T cells induce different types of graft-versus-host disease. J. Immunol. 179: 6547-6554.
38. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J. Immunol. 160: 3444-3452.
39. Kagamu, H., J. E. Touhalisky, G. E. Plautz, J. C. Krauss, and S. Shu. 1996. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 56: 4338-4342. (Pubitemid 26330433)
40. Yang, S., F. Liu, Q. J. Wang, S. A. Rosenberg, and R. A. Morgan. 2011. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS ONE 6: e22560.
41. + T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17: 5343-5352.
42. Figdor, C. G., I. J. de Vries, W. J. Lesterhuis, and C. J. Melief. 2004. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10: 475-480. (Pubitemid 38667904)
43. Montagna, D., R. Maccario, F. Locatelli, V. Rosti, Y. Yang, P. Farness, A. Moretta, P. Comoli, E. Montini, and A. Vitiello. 2001. Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood 98: 3359-3366.
44. Dang, Y., K. L. Knutson, V. Goodell, C. dela Rosa, L. G. Salazar, D. Higgins, J. Childs, and M. L. Disis. 2007. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin. Cancer Res. 13: 1883-1891. (Pubitemid 46952959)
45. Kwak, L. W., D. D. Taub, P. L. Duffey, W. I. Bensinger, E. M. Bryant, C. W. Reynolds, and D. L. Longo. 1995. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345: 1016-1020.
46. + cell fractions of leukapheresis products do not contain malignant cells. Leukemia 11 (Suppl. 5): S41-S46.
47. Leone, F., G. Cavalloni, M. Gunetti, Y. Pignochino, W. Piacibello, and M. Aglietta. 2006. Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors. Biol. Blood Marrow Transplant. 12: 68-74. (Pubitemid 43034099)
48. Ward, R. C., and H. L. Kaufman. 2007. Targeting costimulatory pathways for tumor immunotherapy. Int. Rev. Immunol. 26: 161-196. (Pubitemid 46897676)
49. Westwood, J. A., L. J. Berry, L. X. J. Wang, C. P. M. Duong, H. J. Pegram, P. K. Darcy, and M. H. Kershaw. 2010. Enhancing adoptive immunotherapy of cancer. Expert Opin. Biol. Ther. 10: 531-545.
50. Gattinoni, L., C. A. Klebanoff, and N. P. Restifo. 2012. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12: 671-684.
51. Overwijk, W. W., and K. S. Schluns. 2009. Functions of γC cytokines in immune homeostasis: current and potential clinical applications. Clin. Immunol. 132: 153-165.
52. low tumor-sensitized T lymphocytes following ex vivo hyperexpansion. J. Immunol. 169: 3314-3320.
53. + T cells to regulatory T cells. J. Immunol. 180: 5118-5129.
54. + T cell memory: better living through chemistry. Sci. Transl. Med. 1: 11ps12.
55. Araki, K., A. P. Turner, V. O. Shaffer, S. Gangappa, S. A. Keller, M. F. Bachmann, C. P. Larsen, and R. Ahmed. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460: 108-112.